De Novo Hepatocellular Carcinoma in a Liver Allograft Associated with Recurrent Hepatitis B

Torbenson, Michael; Grover, Davinder S.; Boitnott, J. K.; Klein, Andreas; Molmenti, Ernesto P.

doi:10.1016/j.transproceed.2005.03.093

Cited by 16 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such cases are considered as HCC recurrence and have become a serious problem after LTx for HCC recipients. However, for non-tumor recipients, de novo occurrence of HCC is extremely rare, with only 11 cases reported in recent years [3-11]. In those cases, HCC developed from 3 to 22 years after the patient had received liver transplantation for end-stage liver diseases (HBV-related cirrhosis in four patients, HCV-related cirrhosis in four patients, alcoholic cirrhosis in two patients and Budd-Chiari syndrome in one patient).…”

Section: Discussionmentioning

confidence: 99%

“…Most of the reported de novo HCC cases were related to recurrent cirrhosis, either alcohol or viral related due to recurrent HBV or HCV infection [3,4,7,8]. Morita et al .…”

Section: Discussionmentioning

confidence: 99%

“…However, de novo HCC originating from liver allograft in a patient who received LTx for benign disease has only rarely been reported. To date, there have only been 11 cases of de novo HCC after LTx, reported in 8 papers in the literature [3-11]. In this paper, we report an additional case of de novo HCC developed after liver graft in the setting of hepatitis B (HBV) recurrence after living donor liver transplantation (LDLT) for HBV-related end-stage liver cirrhosis with viral YMDD mutation.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Guo

et al. 2013

World J Surg Onc

View full text Add to dashboard Cite

Post-transplant malignancy is the major cause of later death of recipients after liver transplantation. Tumor recurrence after liver transplantation for patients with hepatocellular carcinoma in the end stage of cirrhosis has been frequently encountered. However, de novo hepatocellular carcinoma originating from the liver allograft has only rarely been reported. Here we reported a case of de novo hepatocellular carcinoma developed 2 years after living donor liver transplantation for hepatitis B-related liver cirrhosis with viral YMDD mutation. To the best of our knowledge, this is the first report of de novo hepatocellular carcinoma in a liver graft with recurrent hepatitis B virus infection after liver transplantation for hepatitis B-related liver cirrhosis with YMDD mutation. Moreover, the de novo cancer first presented as a lung mass with minimal liver involvement and was obscured by a pulmonary fungal infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Most of the reported de novo HCC cases were related to recurrent cirrhosis, either alcohol or viral related due to recurrent HBV or HCV infection [3,4,7,8]. Morita et al .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Guo

et al. 2013

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…To best our knowledge, nine patients with de novo HCC developing in the liver allograft were reported [1][2][3][4][5][6][7] including our case [7] (Table 1). Five of these eventually underwent liver retransplantation; of these, two were free of recurrent HCC when the paper of Croitoru et al [1] was published.…”

mentioning

confidence: 84%

Management of De novo Hepatocellular Carcinoma Developing in a Transplanted Liver

Kita

Yanaga

2007

Dig Dis Sci

View full text Add to dashboard Cite

“…These true de novo HCC can be associated with recurrent hepatitis B [34] or with sustained hepatitis C virus clearance after liver transplantation [35] . They can also be associated with cirrhosis linked to recurrent hepatitis B [36] or C. To distinguish de novo HCC from recurrent HCC, a useful clinical element is the mean time-lapse to occurrence, which is around 5 years after liver transplantation for de novo HCC as opposed to approximately 2 years for recurrent HCC [35] .…”

Section: Cancers That Develop In the Transplantsmentioning

confidence: 99%

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Lebœuf

Ratajczak²,

Verine³

et al. 2014

Pathobiology

View full text Add to dashboard Cite

and the recipient. The results of different studies address the cancers that develop in both recipients and in transplants. The presence of chimeric cells in these two types of cancer implies an exchange of progenitor/stem-cells between transplant and recipient, and the plasticity of these progenitor/stem-cells contributes to epithelial cancers. The presence of chimeric cells in concomitant cancers and preneoplastic lesions implies that the oncogenesis of these cancers progresses through a multistep process.

show abstract

De Novo Hepatocellular Carcinoma in a Liver Allograft Associated with Recurrent Hepatitis B

Cited by 16 publications

References 9 publications

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Management of De novo Hepatocellular Carcinoma Developing in a Transplanted Liver

Assessment of Chimerism in Epithelial Cancers in Transplanted Patients

Contact Info

Product

Resources

About